Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)

• Status: Completed
• Trial end date: 2021-03-25
• Target enrollment: 0
• Participant gender: All

Summary

This work is aimed at improving the quality of life of older patients affected by type 2 diabetes. The investigators will try to amiliorate the complexity of hypogliceamic treatment in a little group of older patients with type 2 diabetes reducing the number of pills and/or insulin administration using a single daily dose of a fixed combination of insulin degludec and liraglutide. This therapeutic semplification will be done indipendently of pre-existent glicaemic control.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Stefano Rizza
• Treatments: Insulin; Liraglutide; Xultophy

Criteria

Inclusion Criteria:

• frail very old type 2 diabetes patients without severe cognitive impairment and/or grave depression with 3 or more daily hypoglycaemic drug administrations

Exclusion Criteria:

• e-GFR < 15 ml/min

• any experimental clinical trial participation or every experimental drug use in the previous 6 months before commencing this study

• every know or suspected allergic reaction to deglutec or any other GLP-1 agonist

• any known contraindication to IDegLira use (as described in product characteristics)

• Recent cancer diagnosis (<3 y) or active radio- or chemo-therapy. Cancer diagnosis older than 3 years before commencing the study is allowed

• Mini mental state examination score lower than 14/30 and/or Activity Daily Living score lower than 1/6 and/or Instrumenctal Activity Daily Living lower than 1/8